$1.77
0.169.94%
At close: -
$1.75
-0.02-1.14%
After Hours: 7:32 PM EDT
Comments
Loading...
Inovio Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:INO | Benzinga
Inovio Pharmaceuticals Inc has a consensus price target of $15.13 based on the ratings of 9 analysts. The high is $40 issued by Oppenheimer on March 8, 2024. The low is $2 issued by B of A Securities on November 1, 2022. The 3 most-recent analyst ratings were released by RBC Capital, HC Wainwright & Co., and Citizens Capital Markets on March 19, 2025, March 19, 2025, and March 14, 2025, respectively. With an average price target of $8.67 between RBC Capital, HC Wainwright & Co., and Citizens Capital Markets, there's an implied 395.27% upside for Inovio Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
HC Wainwright & Co.
Citizens Capital Markets
JMP Securities
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Inovio Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/19/2025 | Buy Now | 185.73% | RBC Capital | Gregory Renza44% | $6 → $5 | Maintains | Sector Perform | Get Alert |
| 03/19/2025 | Buy Now | 71.44% | HC Wainwright & Co. | Raghuram Selvaraju41% | $3 → $3 | Reiterates | Neutral → Neutral | Get Alert |
| 03/14/2025 | Buy Now | 928.63% | Citizens Capital Markets | Roy Buchanan33% | $18 → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/13/2025 | Buy Now | 71.44% | HC Wainwright & Co. | Raghuram Selvaraju41% | $5 → $3 | Maintains | Neutral | Get Alert |
| 01/10/2025 | Buy Now | 928.63% | JMP Securities | Roy Buchanan33% | $18 → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/18/2024 | Buy Now | 185.73% | HC Wainwright & Co. | Raghuram Selvaraju41% | $12 → $5 | Maintains | Neutral | Get Alert |
| 11/18/2024 | Buy Now | 757.19% | Oppenheimer | Jay Olson61% | $33 → $15 | Maintains | Outperform | Get Alert |
| 11/15/2024 | Buy Now | 242.88% | RBC Capital | Gregory Renza44% | $7 → $6 | Maintains | Sector Perform | Get Alert |
| 10/04/2024 | Buy Now | 300.02% | RBC Capital | Gregory Renza44% | $8 → $7 | Maintains | Sector Perform | Get Alert |
| 08/12/2024 | Buy Now | 1785.82% | Oppenheimer | Jay Olson61% | $40 → $33 | Maintains | Outperform | Get Alert |
| 08/09/2024 | Buy Now | 357.17% | RBC Capital | Gregory Renza44% | $11 → $8 | Maintains | Sector Perform | Get Alert |
| 07/15/2024 | Buy Now | 757.19% | HC Wainwright & Co. | Raghuram Selvaraju41% | $15 → $15 | Reiterates | Neutral → Neutral | Get Alert |
| 05/14/2024 | Buy Now | 1042.92% | Stephens & Co. | Sudan Loganathan25% | → $20 | Initiates | → Overweight | Get Alert |
| 03/08/2024 | Buy Now | 2185.84% | Oppenheimer | Hartaj Singh46% | $40 → $40 | Maintains | Outperform | Get Alert |
| 03/07/2024 | Buy Now | 528.61% | RBC Capital | Gregory Renza44% | → $11 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 01/25/2024 | Buy Now | 128.58% | Oppenheimer | Hartaj Singh46% | → $4 | Upgrade | Perform → Outperform | Get Alert |
| 01/04/2024 | Buy Now | -42.85% | JMP Securities | Roy Buchanan33% | → $12 | Initiates | → Market Outperform | Get Alert |
| 05/11/2023 | Buy Now | 14.29% | RBC Capital | Gregory Renza44% | → $24 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/02/2023 | Buy Now | 14.29% | RBC Capital | Gregory Renza44% | $36 → $24 | Maintains | Sector Perform | Get Alert |
| 11/09/2022 | Buy Now | — | Maxim Group | Jason McCarthy41% | — | Downgrade | Buy → Hold | Get Alert |
| 11/01/2022 | Buy Now | 14.29% | B of A Securities | Geoff Meacham60% | → $24 | Downgrade | Neutral → Underperform | Get Alert |
| 08/10/2022 | Buy Now | 71.44% | RBC Capital | Gregory Renza44% | $48 → $36 | Maintains | Sector Perform | Get Alert |
| 05/11/2022 | Buy Now | — | Oppenheimer | Hartaj Singh46% | — | Downgrade | Outperform → Perform | Get Alert |
FAQ
What is the target price for Inovio Pharmaceuticals (INO) stock?
The latest price target for Inovio Pharmaceuticals (NASDAQ:INO) was reported by RBC Capital on March 19, 2025. The analyst firm set a price target for $5.00 expecting INO to rise to within 12 months (a possible 185.73% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inovio Pharmaceuticals (INO)?
The latest analyst rating for Inovio Pharmaceuticals (NASDAQ:INO) was provided by RBC Capital, and Inovio Pharmaceuticals maintained their sector perform rating.
When was the last upgrade for Inovio Pharmaceuticals (INO)?
The last upgrade for Inovio Pharmaceuticals Inc happened on January 25, 2024 when Oppenheimer raised their price target to $4. Oppenheimer previously had a perform for Inovio Pharmaceuticals Inc.
When was the last downgrade for Inovio Pharmaceuticals (INO)?
The last downgrade for Inovio Pharmaceuticals Inc happened on November 9, 2022 when Maxim Group changed their price target from N/A to N/A for Inovio Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Inovio Pharmaceuticals (INO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inovio Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inovio Pharmaceuticals was filed on March 19, 2025 so you should expect the next rating to be made available sometime around March 19, 2026.
Is the Analyst Rating Inovio Pharmaceuticals (INO) correct?
While ratings are subjective and will change, the latest Inovio Pharmaceuticals (INO) rating was a maintained with a price target of $6.00 to $5.00. The current price Inovio Pharmaceuticals (INO) is trading at is $1.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.